Patterns of Late Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with T-Cell Prolymphocytic Leukemia

被引：7

作者：

Shumilov, Evgenii ^{[1
]}

Hasenkamp, Justin ^{[1
]}

Szuszies, Christoph Johannes ^{[1
]}

Koch, Raphael ^{[1
]}

Wulf, Gerald Georg ^{[1
]}

机构：

[1] Univ Med Gottingen, Dept Hematol & Med Oncol, Robert Koch Str 40, DE-37075 Gottingen, Germany

来源：

ACTA HAEMATOLOGICA | 2021年 / 144卷 / 01期

关键词：

T-cell prolymphocytic leukemia (T-PLL); Alemtuzumab; Allogeneic hematopoietic stem cell transplantation; Donor lymphocyte infusion; JAK3;

D O I：

10.1159/000506302

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Initial treatment with the monoclonal anti-CD52 antibody alemtuzumab induces responses in the majority of patients with T-cell prolymphocytic leukemia (T-PLL). In eligible patients, allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an option to consolidate hematological remissions. Here, we report our experience with 10 patients who received allo-HSCT against T-PLL. Notably, 3 patients with complete remission at transplantation and durable full-donor chimerism relapsed at months 12, 59, and 84 after transplantation, respectively. This relapse was associated with rapid progressive leukemia in 1 patient and extralymphatic lymphoma growth in the other 2. Despite CD52 positivity at relapse, alemtuzumab retreatment, donor lymphocyte infusions, and/or chemotherapy including salvage therapy, allo-HSCT yielded a transient partial response, only. Alemtuzumab induction and consolidative allo-HSCT enabled prolonged disease-free survival in these patients but failed to procure cure.

引用

页码：105 / 110

页数：6

共 23 条

[1] Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling [J].

Andersson, E. I. ;

Puetzer, S. ;

Yadav, B. ;

Dufva, O. ;

Khan, S. ;

He, L. ;

Sellner, L. ;

Schrader, A. ;

Crispatzu, G. ;

Oles, M. ;

Zhang, H. ;

Adnan-Awad, S. ;

Lagstrom, S. ;

Bellanger, D. ;

Mpindi, J. P. ;

Eldfors, S. ;

Pemovska, T. ;

Pietarinen, P. ;

Lauhio, A. ;

Tomska, K. ;

Cuesta-Mateos, C. ;

Faber, E. ;

Koschmieder, S. ;

Bruemmendorf, T. H. ;

Kytola, S. ;

Savolainen, E-R ;

Siitonen, T. ;

Ellonen, P. ;

Kallioniemi, O. ;

Wennerberg, K. ;

Ding, W. ;

Stern, M-H ;

Huber, W. ;

Anders, S. ;

Tang, J. ;

Aittokallio, T. ;

Zenz, T. ;

Herling, M. ;

Mustjoki, S. .

LEUKEMIA, 2018, 32 (03) :774-787

[2] Recurrent Mutation of JAK3 in T-Cell Prolymphocytic Leukemia [J].

Bergmann, Anke K. ;

Schneppenheim, Sina ;

Seifert, Marc ;

Betts, Matthew J. ;

Haake, Andrea ;

Lopez, Cristina ;

Penas, Eva Maria Murga ;

Vater, Inga ;

Jayne, Sandrine ;

Dyer, Martin J. S. ;

Schrappe, Martin ;

Duehrsen, Ulrich ;

Ammerpohl, Ole ;

Russell, Robert B. ;

Kueppers, Ralf ;

Duerig, Jan ;

Siebert, Reiner .

GENES CHROMOSOMES & CANCER, 2014, 53 (04) :309-316

[3]

Boidol B, 2017, BLOOD, V130

[4] T-cell prolymphocytic leukemia [J].

Dearden, CE .

MEDICAL ONCOLOGY, 2006, 23 (01) :17-22

[5] High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H [J].

Dearden, CE ;

Matutes, E ;

Cazin, B ;

Tjonnfjord, GE ;

Parreira, A ;

Nomdedeu, B ;

Leoni, P ;

Clark, FJ ;

Radia, D ;

Rassam, SMB ;

Roques, T ;

Ketterer, N ;

Brito-Babapulle, V ;

Dyer, MJS ;

Catovsky, D .

BLOOD, 2001, 98 (06) :1721-1726

[6] Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route [J].

Dearden, Claire E. ;

Khot, Amit ;

Else, Monica ;

Hamblin, Mike ;

Grand, Effie ;

Roy, Ashok ;

Hewamana, Saman ;

Matutes, Estella ;

Catovsky, Daniel .

BLOOD, 2011, 118 (22) :5799-5802

[7] Allogeneic hematopoietic stem cell transplantation for T-prolymphocytic leukemia: a report from the French society for stem cell transplantation (SFGM-TC) [J].

Guillaume, Thierry ;

Beguin, Yves ;

Tabrizi, Reza ;

Nguyen, Stephanie ;

Blaise, Didier ;

Deconinck, Eric ;

Redjoul, Rabah ;

Cornillon, Jerome ;

Guillerm, Gaelle ;

Contentin, Nathalie ;

Sirvent, Anne ;

Turlure, Pascal ;

Salmon, Alexandra ;

Anne Huynh ;

Francois, Sylvie ;

de Latour, Regis Peffault ;

Yakoub-Agha, Ibrahim ;

Mohty, Mohamad .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2015, 94 (03) :265-269

[8] Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL) [J].

Jain, P. ;

Aoki, E. ;

Keating, M. ;

Wierda, W. G. ;

O'Brien, S. ;

Gonzalez, G. N. ;

Ferrajoli, A. ;

Jain, N. ;

Thompson, P. A. ;

Jabbour, E. ;

Kanagal-Shamanna, R. ;

Pierce, S. ;

Alousi, A. ;

Hosing, C. ;

Khouri, I. ;

Estrov, Z. ;

Cortes, J. ;

Kantarjian, H. ;

Ravandi, F. ;

Kadia, T. M. .

ANNALS OF ONCOLOGY, 2017, 28 (07) :1554-1559

[9] Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed [J].

Keating, MJ ;

Cazin, B ;

Coutré, S ;

Birhiray, R ;

Kovacsovics, T ;

Langer, W ;

Leber, B ;

Maughan, T ;

Rai, K ;

Tjonnfjord, G ;

Bekradda, M ;

Itzhaki, M ;

Hérait, P .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (01) :205-213

[10] Genes encoding members of the JAK-STAT pathway or epigenetic regulators are recurrently mutated in T-cell prolymphocytic leukaemia [J].

Lopez, Cristina ;

Bergmann, Anke K. ;

Paul, Ulrike ;

Penas, Eva M. Murga ;

Nagel, Inga ;

Betts, Matthew J. ;

Johansson, Patricia ;

Ritgen, Matthias ;

Baumann, Tycho ;

Aymerich, Marta ;

Jayne, Sandrine ;

Russell, Robert B. ;

Campo, Elias ;

Dyer, Martin J. S. ;

Duerig, Jan ;

Siebert, Reiner .

BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 (02) :265-273

← 1 2 3 →